San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor during the weight loss drug current market in February right after revealing promising data from a mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented as a weekly injection As well as